CDDD11-8 is an orally effective and selective inhibitor of CDK9 and FLT3-ITD (with Ki values of 8 nM and 13 nM, respectively); it reduces the proliferation of leukemia cell lines and shows particular efficacy against those harboring FLT3-ITD mutations.